Company news

Oncoinvent ASA news in 2025

Oncoinvent ASA's news releases, calls and decks from 2025, newest first.

View company

Oncoinvent ASA: Grant of share options – mandatory notification of trade

December 22, 2025

Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer

October 8, 2025

Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer

August 27, 2025

Announcement of fully underwritten rights issue

June 30, 2025

Calls in 2025

Decks in 2025